Pfizer Bids Farewell To Blue Pill With New Double Helix Logo
'Reveals DNA At Heart' Of Science-Focused Firm
Executive Summary
CEO Albert Bourla says the rebranding "marks the advent of the new Pfizer – the culmination of a bold, decade-long transformation from a scientific fast follower to a first-in-class scientific powerhouse."
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest major developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.